CRISPR Therapeutics AG
$57.69
▲
1.43%
2026-04-21 06:14:01
www.crisprtx.com
NGM: CRSP
Explore CRISPR Therapeutics AG stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.56 B
Current Price
$57.69
52W High / Low
$78.48 / $33.03
Stock P/E
—
Book Value
$20.04
Dividend Yield
—
ROCE
-31.41%
ROE
-30.18%
Face Value
—
EPS
$-6.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.79
Debt / Equity
10.76
Current Ratio
13.32
Quick Ratio
13.32
Forward P/E
-12.23
Price / Sales
1,400.67
Enterprise Value
$3.15 B
EV / EBITDA
-5.73
EV / Revenue
896.66
Rating
Buy
Target Price
$83.35
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Beam Therapeutics Inc. | $31.19 | — | $3.2 B | — | -27.72% | -8.11% | $36.44 / $15.35 | $12.48 |
| 2. | Unicycive Therapeutics, Inc. | $7.43 | — | $177.17 M | — | -97.75% | -1.41% | $11 / $3.71 | $1.36 |
| 3. | C4 Therapeutics, Inc. | $2.99 | — | $284.93 M | — | -32.05% | -44.44% | $3.82 / $1.09 | $2.65 |
| 4. | Arrowhead Pharmaceuticals, Inc. | $71.64 | 46.54 | $10.05 B | — | 8.27% | 75.5% | $76.76 / $10.92 | $4.14 |
| 5. | Protalix BioTherapeutics, Inc. | $2.27 | — | $184.11 M | — | -9.85% | -14.44% | $3.19 / $1.32 | $0.6 |
| 6. | Arcturus Therapeutics Holdings Inc. | $8.9 | — | $251.54 M | — | -32.48% | -28.92% | $24.17 / $5.85 | $7.53 |
| 7. | Pulmatrix, Inc. | $1.34 | — | $4.91 M | — | -135.67% | -80.93% | $9.37 / $1.16 | $1.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 35 M |
| Operating Profit | -154.76 M | -132.06 M | -229.32 M | -148.42 M | -64.59 M |
| Net Profit | -130.61 M | -106.44 M | -208.55 M | -136 M | -37.31 M |
| EPS in Rs | -1.36 | -1.11 | -2.17 | -1.42 | -0.39 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 35 M | 370 M | 0.44 M |
| Operating Profit | -664.57 M | -466.57 M | -222.54 M | -673.16 M |
| Net Profit | -581.6 M | -366.25 M | -153.61 M | -650.17 M |
| EPS in Rs | -6.06 | -3.82 | -1.6 | -6.77 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.27 B | 2.24 B | 2.23 B | 2.24 B |
| Total Liabilities | 343.43 M | 309.95 M | 346.77 M | 367.58 M |
| Equity | 1.92 B | 1.93 B | 1.88 B | 1.88 B |
| Current Assets | 1.99 B | 1.94 B | 1.91 B | 1.85 B |
| Current Liabilities | 149.12 M | 87.78 M | 108.79 M | 121.11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -345.01 M | -142.77 M | -260.38 M | -495.74 M |
| Investing CF | -31.8 M | -280.48 M | 374.65 M | -258.65 M |
| Financing CF | 426.03 M | 331.98 M | 62.66 M | 38.59 M |
| Free CF | -370.93 M | -144.68 M | -272.35 M | -532.93 M |
| Capex | -25.91 M | -1.9 M | -11.97 M | -37.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -90.54% | 84762.39% | — |
| Earnings Growth % | -58.8% | -138.43% | 76.37% | — |
| Profit Margin % | — | -1046.43% | -41.52% | -149122.71% |
| Operating Margin % | — | -1333.05% | -60.15% | -154394.72% |
| Gross Margin % | — | -244.76% | 64.8% | -25186.7% |
| EBITDA Margin % | — | -1278.02% | -54.78% | -148850.69% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.